Tear Film Innovations has completed $8.5 million in Series B funding, the company announced in a press release.
Led by Visionary Ventures Fund and Bluestem Capital, the funding will be used as growth capital for the iLux evaporative dry eye system, which received 510(k) clearance from the FDA in December 2017 and provides targeted therapy to blocked meibomian glands through an in-office treatment.
“The early, enthusiastic response to the iLux system from both the ophthalmic and optometric sectors is very encouraging,” OSN Chief Medical Editor Richard L. Lindstrom, MD, a (Read more...)
Uncategorized